Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA

被引:182
作者
Wong, Danny Ka-Ho [1 ,2 ]
Seto, Wai-Kay [1 ,2 ]
Cheung, Ka-Shing [1 ]
Chong, Chun-Kong [1 ]
Huang, Fung-Yu [1 ]
Fung, James [1 ,2 ]
Lai, Ching-Lung [1 ,2 ]
Yuen, Man-Fung [1 ,2 ]
机构
[1] Univ Hong Kong, Dept Med, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Hong Kong, Peoples R China
关键词
covalently closed circular DNA; hepatitis B; hepatitis B core-related antigen; hepatitis B serum markers; intrahepatic HBV DNA; SURFACE-ANTIGEN; NUCLEOS(T)IDE ANALOGS; NATURAL-HISTORY; LAMIVUDINE; HBSAG; CCCDNA; REDUCTION; THERAPY; RISK; QUANTIFICATION;
D O I
10.1111/liv.13346
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) is a key to viral persistence in chronic hepatitis B infection. Serum hepatitis B core-related antigen (HBcrAg) is a novel marker for HBV disease. We aimed to determine whether HBcrAg could be a surrogate marker for intrahepatic cccDNA. Methods: Three hundred and five liver biopsies and the corresponding sera collected from 138 nucleos(t)ide analogues-treated patients were analysed. 124 patients had paired liver biopsies at baseline and 1-year post-treatment, and 43 patients had a third biopsy after 6-12years of treatment. Serum HBcrAg, HBV DNA and hepatitis B surface antigen (HBsAg), and intrahepatic HBV DNA and cccDNA were measured. Results: HBcrAg strongly correlated with cccDNA (r=.70), intrahepatic total HBV DNA (r=.67) and serum HBV DNA (r=.69; all P<.0001). In the 130 samples with undetectable serum HBV DNA, HBcrAg was detectable in 101 (78%) samples, and HBcrAg levels still correlated positively with cccDNA (r=.42, P<.0001). At 6years of therapy, the median logarithmic reduction in HBcrAg was 2.7log kU/mL, which was comparable to the magnitude of reduction in cccDNA. Twenty-one patients had undetectable cccDNA after 6years of treatment, in whom 15 (71%) had detectable HBcrAg (range: 1.2-537kU/mL). Conclusions: Serum HBcrAg is a reliable surrogate marker for intrahepatic cccDNA. HBcrAg could be a very sensitive marker to reflect the cccDNA content and persistence of disease even with the cccDNA levels below the detection limit of assays.
引用
收藏
页码:995 / 1001
页数:7
相关论文
共 32 条
[1]   Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon- [J].
Caviglia, Gian Paolo ;
Abate, Maria Lorena ;
Noviello, Daniele ;
Olivero, Antonella ;
Rosso, Chiara ;
Troshina, Giulia ;
Ciancio, Alessia ;
Rizzetto, Mario ;
Saracco, Giorgio Maria ;
Smedile, Antonina .
HEPATOLOGY RESEARCH, 2017, 47 (08) :747-754
[2]   Hepatitis B surface antigen quantification: Why and how to use it in 2011-A core group report [J].
Chan, Henry Lik-Yuen ;
Thompson, Alex ;
Martinot-Peignoux, Michelle ;
Piratvisuth, Teerha ;
Cornberg, Markus ;
Brunetto, Maurizia Rossana ;
Tillmann, Hans L. ;
Kao, Jia-Horng ;
Jia, Ji-Dong ;
Wedemeyer, Heiner ;
Locarnini, Stephen ;
Janssen, Harry L. A. ;
Marcellin, Patrick .
JOURNAL OF HEPATOLOGY, 2011, 55 (05) :1121-1131
[3]   A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B [J].
Chang, TT ;
Gish, RG ;
de Man, R ;
Gadano, A ;
Sollano, J ;
Chao, YC ;
Lok, AS ;
Han, KH ;
Goodman, Z ;
Zhu, J ;
Cross, A ;
DeHertogh, D ;
Wilber, R ;
Colonno, R ;
Apelian, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1001-1010
[4]   Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [J].
Chen, CJ ;
Yang, HI ;
Su, J ;
Jen, CL ;
You, SL ;
Lu, SN ;
Huang, GT ;
Iloeje, UH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01) :65-73
[5]   Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: Finite treatment duration unlikely [J].
Chevaliez, Stephane ;
Hezode, Christophe ;
Bahrami, Stephane ;
Grare, Marion ;
Pawlotsky, Jean-Michel .
JOURNAL OF HEPATOLOGY, 2013, 58 (04) :676-683
[6]   Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B [J].
Chuaypen, Natthaya ;
Sriprapun, Methee ;
Praianantathavorn, Kesmanee ;
Payungporn, Sunchai ;
Wisedopas, Naruemon ;
Poovorawan, Yong ;
Tangkijvanich, Pisit .
JOURNAL OF MEDICAL VIROLOGY, 2017, 89 (01) :130-138
[7]   Correlation between intrahepatic hepatitis B virus cccDNA levels and other activity markers in patients with HBeAg-negative chronic hepatitis B infection [J].
Guner, Rahmet ;
Karahocagil, Mustafa ;
Buyukberber, Mehmet ;
Kandemir, Ozlem ;
Ural, Onur ;
Usluer, Gaye ;
Inan, Dilara ;
Koksal, Iftihar ;
Baykam, Nurcan ;
Hizel, Kenan ;
Yamazhan, Tansu ;
Esen, Saban ;
Tasyaran, Mehmet A. .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2011, 23 (12) :1185-1191
[8]   Predicting cirrhosis risk based on the level of circulating hepatitis B viral load [J].
Iloeje, UH ;
Yang, HI ;
Su, J ;
Jen, CL ;
You, SL ;
Chen, CJ .
GASTROENTEROLOGY, 2006, 130 (03) :678-686
[9]   Hepatitis B virus DNA-negative Dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain [J].
Kimura, T ;
Ohno, N ;
Terada, N ;
Rokuhara, A ;
Matsumoto, A ;
Yagi, S ;
Tanaka, E ;
Kiyosawa, K ;
Ohno, S ;
Maki, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (23) :21713-21719
[10]   Telbivudine versus lamivudine in patients with chronic hepatitis B [J].
Lai, Ching-Lung ;
Gane, Edward ;
Liaw, Yun-Fan ;
Hsu, Chao-Wei ;
Thongsawat, Satawat ;
Wang, Yuming ;
Chen, Yagang ;
Heathcote, E. Jenny ;
Rasenack, Jens ;
Bzowej, Natalie ;
Naoumov, Nikolai V. ;
Di Bisceglie, Adrian M. ;
Zeuzem, Stefan ;
Moon, Young Myoung ;
Goodman, Zachary ;
Chao, George ;
Constance, Barbara Fielman ;
Brown, Nathaniel A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (25) :2576-2588